Thank you to Prof. Rustam Salman for speaking to us about the RESTART trial, which compared starting versus avoiding antiplatelet therapy for adults surviving antithrombotic-associated ICH.

This was NANSIG's second journal club - we thank you for tuning in live or through this catch-up format, and hope you'll join us for more discussions!

Please like and subscribe to our channel for more content. Thank you!

свернуть